Andrea G. Barbo
University of Texas MD Anderson Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrea G. Barbo.
Journal of Viral Hepatitis | 2015
Jessica P. Hwang; Andrea G. Barbo; Robert P. Perrillo
Hepatitis B virus reactivation (HBVr) can be a serious complication of cancer chemotherapy. However, underutilization of HBV screening and secondary underutilization of antiviral prophylaxis have been frequently reported. The authors electronically distributed a 30‐point questionnaire to members of the American Association for the Study of Liver Diseases to capture experiences with HBVr during cancer chemotherapy. The questionnaire specified diagnostic criteria and collected information on HBV screening, antiviral prophylaxis and clinical outcomes. Ninety‐nine respondents reported 188 patients who met the criteria for HBV reactivation. Forty‐one practised outside the United States, and most were hepatologists (n = 71) or gastroenterologists (n = 12). One hundred and twenty‐six patients had haematologic malignancies, of which 88 (70%) had lymphoma. Seventy‐five patients (40%) had screening for both hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti‐HBc), and an additional 24 patients (13%) had HBsAg screening alone. Prophylactic antiviral therapy was reported in only 18 patients (10%). Chemotherapy was interrupted in 52 patients (41%) with haematologic malignancies and 26 of 41 patients (63%) with solid tumours (P = 0.01). Rituximab‐treated patients (n = 66) required hospitalization more frequently (P = 0.04), but their overall survival did not differ from individuals not treated with rituximab. Death due to liver failure was reported in 43 patients overall (23%). Underutilization of prophylactic antiviral therapy occured in a substantial number of patients who were found to be HBV infected prior to the initiation of cancer chemotherapy. The reasons for this need further exploration because reactivation results in serious yet preventable outcomes.
Journal of Clinical Oncology | 2015
Xerxes Pundole; Andrea G. Barbo; Heather Lin; Richard E. Champlin; Huifang Lu
PURPOSE The number of long-term survivors after hematopoietic stem-cell transplantation (HSCT) for malignant and nonmalignant disorders is increasing, and late effects are gaining importance. Osteoporosis and fractures can worsen the quality of life of HSCT survivors, but the burden of the disease is unknown. PATIENTS AND METHODS We conducted a retrospective study of patients older than age 18 years who underwent an HSCT at The University of Texas MD Anderson Cancer Center from January 1, 1997, to December 31, 2011, and were observed until December 31, 2013, to ascertain occurrence of fractures. Cumulative incidence rates of fractures were calculated with death as a competing risk. Age- and sex-specific incidence rates per person-year of fracture were compared with those of the US general population by using estimated rates from the 1994 National Health Interview Survey and the 2004 National Hospital Discharge Survey. RESULTS A total of 7,620 patients underwent an HSCT from 1997 to 2011 at the MD Anderson Cancer Center of whom 602 (8%) developed a fracture. Age, underlying disease, and HSCT type were significantly associated with fracture. Age- and sex-specific fracture incidence rates after HSCT were significantly greater than those of the US general population in almost all subgroups. The striking difference was an approximately eight times greater risk in females and approximately seven to nine times greater risk in males age 45 to 64 years old when compared with the National Health Interview Survey and National Hospital Discharge Survey fracture rates. CONCLUSION The incidence of fractures is compellingly higher after HSCT.
Arthritis Care and Research | 2018
Maria A. Lopez-Olivo; Aparna Ingleshwar; Robert J. Volk; Maria L. Jibaja-Weiss; Andrea G. Barbo; Kenneth G. Saag; Amye Leong; Maria E. Suarez-Almazor
We developed and tested multimedia patient education tools (video tools) for patients with knee osteoarthritis (OA), osteoporosis (OP), and rheumatoid arthritis (RA).
The Journal of Rheumatology | 2016
Christian A. Waimann; Rodrigo J. Fernandez-Mazarambroz; Scott B. Cantor; Maria A. Lopez-Olivo; Andrea G. Barbo; Glenn C. Landon; Sherwin J. Siff; Heather Lin; Maria E. Suarez-Almazor
Objective. Clinical and psychosocial attributes are associated with clinical outcomes after total knee replacement (TKR) surgery in patients with osteoarthritis (OA), but their relationship with TKR-related costs is less clear. Our objective was to evaluate the effect of clinical and psychosocial attributes on TKR costs. Methods. We conducted a 6-month prospective cohort study of patients with knee OA who underwent TKR. We examined baseline demographic, clinical [body mass index (BMI) and comorbidities], and psychosocial attributes (social support, locus of control, coping, depression, anxiety, stress, and self-efficacy); baseline and 6-month OA clinical outcomes [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function]; and 6-month direct and indirect TKR-related costs. Multiple regression was performed to identify determinants of TKR-related costs. Results. We included 212 patients; 66% were women, 71% were white, and the mean age was 65.2 years. The mean baseline WOMAC pain score was 55 (SD 19) and WOMAC function score was 54 (SD 20). Mean total TKR-related costs were US
Jcr-journal of Clinical Rheumatology | 2015
Richard L. Street; Maria F. Marengo; Andrea G. Barbo; Heather Lin; Araceli Garcia Gonzalez; Marsha Richardson; Maria E. Suarez-Almazor
30,831 (SD
Scientific Reports | 2017
Gustavo Schvartsman; Michael J. Wagner; Behrang Amini; Chrystia Zobniw; Van Anh Trinh; Andrea G. Barbo; Heather Lin; Wei Lien Wang; Anthony P. Conley; Vinod Ravi; Dejka M. Araujo; Maria Alejandra Zarzour; Robert S. Benjamin; Shreyaskumar Patel; Neeta Somaiah
9893). Multivariate regression analyses showed that increasing BMI and anxiety levels and decreasing levels of positive social interactions were associated with increased costs. A lower cost scenario with a lower range of normal BMI (19.5), highest positive social interaction, and no anxiety predicted TKR costs to be
Scientific Reports | 2017
John A. Livingston; D. Bugano; Andrea G. Barbo; Heather Lin; John E. Madewell; Wei-Lien Wang; Alexander J. Lazar; William W. Tseng; Christina L. Roland; Barry W. Feig; Raphael E. Pollock; Anthony P. Conley; Robert S. Benjamin; Shreyaskumar Patel; Neeta Somaiah
22,247. Predicted costs in obese patients (BMI 36) with lowest positive social interaction and highest anxiety were
Cancer | 2017
Jessica P. Hwang; Maria E. Suarez-Almazor; Scott B. Cantor; Andrea G. Barbo; Heather Lin; Sairah Ahmed; Mariana Chavez-MacGregor; Christian Donato-Santana; Cathy Eng; Alessandra Ferrajoli; Michael J. Fisch; Peter McLaughlin; George R. Simon; Gabriela Rondon; Elizabeth J. Shpall; Anna S. Lok
58,447. Conclusion. Increased baseline BMI, anxiety, and poor social support lead to higher TKR-related costs in patients with knee OA. Preoperative interventions targeting these factors may reduce TKR-related costs, and therefore be cost-effective.
Arthritis Care and Research | 2016
G.H. Lo; Ajay S. Balasubramanyam; Andrea G. Barbo; Richard L. Street; Maria E. Suarez-Almazor
BackgroundTone of voice in communication between patients and rheumatologists may offer insight into problems of treatment adherence in patients with rheumatoid arthritis. ObjectiveThe aim of this study was to evaluate physician-patient affective vocal tone within the medical encounter and its relationship to treatment adherence in ethnically diverse patients with rheumatoid arthritis. MethodsThe consultations of 174 patients with rheumatoid arthritis were audio recorded at a baseline visit. Of these, 135 completed follow-up adherence measures at 3 months. The positive and negative affective tones of patients, physicians, and interpreters (and distressed tones of patients and interpreters) were assessed using the Roter Interaction Analysis System affective communication scale. Treatment adherence was evaluated at baseline and at 3 months using the Compliance Questionnaire Rheumatology. ResultsA total of 117 baseline consultations were in English (n = 42, 36, and 39 white, African American, and Hispanic patients, respectively), 24 in Spanish, and 33 with an interpreter (total = 174). Patients reporting poorer adherence were rated as having more distressed affect and less positive affect than patients reporting greater adherence. Physicians expressed more positive affect to more educated patients. Physicians and patients reciprocated one another’s positive and negative affect. Controlling for baseline adherence, physician negative affect predicted greater adherence at 3 months for Hispanic patients, regardless of language choice, compared with white patients. ConclusionsPatients’ affective tones offer clues to problems patients may have with treatment adherence and well-being. More research is needed regarding why physicians’ expression of negative affect may facilitate adherence for some groups of patients.
Journal of Oncology Practice | 2015
Jessica P. Hwang; Bruno Granwehr; Harrys A. Torres; Maria E. Suarez-Almazor; Thomas P. Giordano; Andrea G. Barbo; Heather Lin; Michael J. Fisch; Elizabeth Y. Chiao
Regorafenib was approved as third-line therapy for advanced Gastrointestinal Stromal Tumour (GIST) at a starting dose of 160 mg daily 3 weeks on, 1 week off, based on improvement in progression free survival over placebo (4.8 vs. 0.9 months), but the response rate was low at 4.5%. Given the high toxicity rate in GIST patients, there is variability in the post-marketing dosing of regorafenib. We aimed to summarize our experience regarding prescribing patterns, efficacy and toxicity of regorafenib and determine the role of response assessment by Choi criteria in GIST patients. We included 28 patients who received regorafenib from our pharmacy. Baseline patient characteristics and treatment outcomes were recorded and an independent radiologist assessed response using Choi and RECIST. Seventy-nine percent of patients started at a 120 mg continuous daily dosing schedule, different from the standard intermittent dosing schedule. Grade 3/4 adverse events were experienced by 43% of patients. Median progression-free survival was 8.7 months. Continuous dosing with regorafenib at 120 mg daily is the preferred prescribing pattern and appears to be better tolerated and with comparable efficacy to the current standard dose. Similar to imatinib, the partial response rate for regorafenib by Choi (29%) was higher compared to RECIST (4%).